|
A.A. Lyanova, L.Yu. Vladimirova, D.S. Kutilin, N.A. Abramova, I.L. Popova, N.M. Tikhanovskaya, M.A. Teplyakova, K.A. Novoselova, V.S. Myagkova, F.V. Alieva, L.A. Ryadinskaya
The effect of drug therapy and cetuximab on the mutational status of the KRAS gene in patients with squamous cell carcinoma of the tongue and oral floor mucosa
|
№7 / 2021
|
|
V.M. Moiseenko (1), F.V. Moiseenko (1, 2, 3), N.M. Volkov (1), G.A. Yanus (2), E.Sh. Kuligina (2), A.P. Sokolenko (2), S.N. Aleksakhina (2), V.A. Chubenko (1), K.S. Kozyreva (2), N.Kh. Abduloeva (1), M.M. Kramchaninov (1), A.S. Zhuravlev (1), V.A. Khinshtein (1), K.V. Shelekhova (1), A.A. Kudryavtsev (1), A.V. Myslik (1), A.O. Ivantsov (2), A.R. Venina (2), E.V. Preobrazhenskaya (2, 4), N.V. Mityushkina (2), A.G. Ievleva (2, 4), E.N. Imyanitov (2, 4)
Prospective II phase study on the evaluation of the efficacy of monotherapy with cetuximab as the first-line treatment for patients with metastatic colorectal cancer with wild-type KRas, NRas, and BRAF genes
|
№7 / 2018
|
Русский
